Obesity is a growing problem worldwide, tripling over the past few decades with more than a billion people worldwide now classified as obese. Although the health effects can be deadly, many of the proposed solutions such as diet and exercise do not seem to have been effective. Enter Allurion, a company which seeks to end obesity through a "360-degree" approach.
While in current times weight loss is no longer driven by outdated aesthetic considerations, it's still true that diet and exercise alone do not always seem to work and the available alternatives require invasive surgery or endoscopy. This creates a space in the market which Allurion occupies with its combination of non-surgical gastric balloon to physically regulate hunger, app-based health tracker, and personalized nutrition and exercise plan. In over a decade it has treated over 100,000 patients in 60 countries.
Allurion has secured large amounts of investment, pushing its expansion into India and Brazil, and allowing it to hire highly qualified individuals to its board to speed its applications for approval in new markets as well as develop the product. This was followed by an IPO in 2023, boosting its efforts to research AI-based weight loss solutions.
Freddie
Company Specialist at Welcome to the Jungle
